<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25118" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Midazolam</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lingamchetty</surname>
            <given-names>Thejasvi N.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hosseini</surname>
            <given-names>Seyed Alireza</given-names>
          </name>
          <aff>Kern Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thejasvi Lingamchetty declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Seyed Alireza Hosseini declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25118.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Intravenous midazolam is used for the induction of anesthesia and also in the management of acute seizures. Because of its water-soluble nature, midazolam has a rapid onset of action and can be used to manage status epilepticus when intravenous administration of other medications is not feasible. Midazolam can be used for anxiolysis and hypnosis during the maintenance phase of general anesthesia. Midazolam is an adjunct medication to regional and local anesthesia for a wide range of diagnostic and therapeutic procedures and has greater patient and clinician acceptance. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of midazolam, pertinent for members of the interprofessional team in the treatment of patients where it is of clinical value.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the mechanism of action of midazolam.</p></list-item><list-item><p>Describe the various indications where midazolam can be effective.</p></list-item><list-item><p>Review the adverse event profile of midazolam.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to properly use midazolam to improve patient outcomes in the varied scenarios where it can be effective.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25118&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25118">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25118.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Intravenous midazolam is used&#x000a0;for the induction of anesthesia and also in the management of acute seizures. Because of its water-soluble&#x000a0;nature, midazolam has a rapid onset of action and can be used&#x000a0;to&#x000a0;manage status epilepticus when intravenous administration of other medications is not feasible. Midazolam has a high rate of tolerance, and the dose can&#x000a0;be increased to maintain the therapeutic effect. Because of its easy&#x000a0;mode of administration through the buccal and intranasal&#x000a0;routes, it is a viable option in children to manage seizures.&#x000a0;For its use in anesthesia, the&#x000a0;response to the induction dose is more variable compared to thiopental. Midazolam can be used for anxiolysis and hypnosis during the maintenance phase of general anesthesia and is also superior to thiopental in the maintenance of anesthesia because of the less need for adjunct medications. Midazolam is an&#x000a0;adjunct medication to regional and local anesthesia for a wide range of diagnostic and therapeutic procedures and has greater patient and physician acceptance.<xref ref-type="bibr" rid="article-25118.r1">[1]</xref><xref ref-type="bibr" rid="article-25118.r2">[2]</xref><xref ref-type="bibr" rid="article-25118.r3">[3]</xref></p>
      </sec>
      <sec id="article-25118.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Midazolam has poor oral absorption and has an elimination half-life of 1.5&#x000a0;to 2.5 hours.&#x000a0;Midazolam converts into its active metabolite alpha-1 hydroxy midazolam, which contributes to 10% of drug action. Midazolam metabolism occurs via hepatic CYP450 enzymes and glucuronide conjugation. The mechanism of action of midazolam indirect and is related&#x000a0;to GABA accumulation and its affinity to the benzodiazepine receptors. Two separate receptors for GABA and benzodiazepine couple to a common chloride channel. It increases the frequency of chloride channel opening. Occupation of both the receptors cause membrane hyperpolarization and neuronal inhibition. The anticonvulsant activity of midazolam is related to the excess GABA action on motor circuits in the brain. Midazolam acts on glycine receptors and produces a muscle-relaxing&#x000a0;effect. Almost all the pharmacologic effects, including sedation, anxiolysis, anterograde amnesia, and anticonvulsant effect, can are explainable through its action on GABA receptors. Age-related deficits, hepatic, and renal insufficiency, also affect the pharmacokinetics of midazolam.<xref ref-type="bibr" rid="article-25118.r4">[4]</xref><xref ref-type="bibr" rid="article-25118.r5">[5]</xref><xref ref-type="bibr" rid="article-25118.r6">[6]</xref><xref ref-type="bibr" rid="article-25118.r7">[7]</xref>&#x000a0;Midazolam has both hydrophilic and lipophilic properties, depending upon the pH.</p>
      </sec>
      <sec id="article-25118.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Midazolam administration can be through oral, intranasal, buccal, intravenous, and intramuscular routes. For the perioperative use of midazolam, the induction dose is 0.15&#x000a0;to 0.40&#x000a0;mg/kg via the intravenous route. For the premedication, the dose is 0.07&#x000a0;to 0.10 mg/kg with the intramuscular route. For intravenous sedation, the dose is titrated&#x000a0;at 0.05&#x000a0;to 0.15 mg/kg. For children 1&#x000a0;to 5 months old, the recommended intranasal dose is 0.2mg/kg. For children&#x000a0;six months and older, 0.2&#x000a0;to 0.3 mg/kg intranasal dose&#x000a0;is&#x000a0;the recommendation.<xref ref-type="bibr" rid="article-25118.r1">[1]</xref>&#x000a0;Since elderly patients metabolize benzodiazepines more slowly and are more prone to adverse effects, caution is advised when administering the drug in that patient population.</p>
      </sec>
      <sec id="article-25118.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The common adverse effects associated with midazolam use are hiccoughs, cough, nausea, and vomiting. Thrombophlebitis, thrombosis, and pain on injection are other adverse effects. The incidence of thrombophlebitis is less than with diazepam but similar to that of thiopental. Midazolam causes anterograde amnesia, drowsiness, ataxia, falls, and confusion in the elderly. Residual hangover effect can happen with nighttime administration of midazolam, which can impair the cognitive and psychomotor abilities, which can result in&#x000a0;falls in elderly and impaired coordination during driving. Hypotension and tachycardia can occur with rapid intravenous administration. A higher dose&#x000a0;can result in&#x000a0;midazolam infusion syndrome and respiratory depression. Instances of&#x000a0;midazolam infusion syndrome require continuous ventilator&#x000a0;support. Paradoxical effects of midazolam are possible in individuals with a history of alcohol abuse and aggressive behavior, potentially leading to involuntary movements, verbalization, uncontrollable crying, and aggressive behavior. Respiratory depression can happen with a dose of 0.15 mg/kg, and the risk increases when used along with fentanyl. Concomitant use of midazolam with other CNS depressants can result in severe respiratory depression and death even at therapeutic doses.</p>
        <p>Long-term use of midazolam is associated with lasting memory deficits, which are only partially reversible after discontinuing the drug. For pregnant women, the administration of the drug in the third trimester causes benzodiazepine withdrawal syndrome in the neonate resulting in hypotonia, cyanosis, and apnoeic spells. Neonates may suffer from diarrhea, tremors, and hyperexcitability. About one-third of individuals receiving midazolam can suffer from tolerance after using the drug for four weeks. Withdrawal syndrome can occur if the dose tapers too rapidly. Symptoms due to the withdrawal of benzodiazepine include irritability, clonus, hypertonicity, nausea, vomiting, diarrhea, tachycardia, and hypertension. Sudden discontinuation of midazolam can result in&#x000a0;status epilepticus.<xref ref-type="bibr" rid="article-25118.r8">[8]</xref><xref ref-type="bibr" rid="article-25118.r9">[9]</xref><xref ref-type="bibr" rid="article-25118.r10">[10]</xref><xref ref-type="bibr" rid="article-25118.r11">[11]</xref></p>
      </sec>
      <sec id="article-25118.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications for the use of midazolam include acute angle-closure glaucoma, hypotension, and shock. Careful dose adjustment is necessary in cases of kidney and liver diseases, alcohol, and drug-dependent individuals. Caution is necessary for pregnant individuals, children, and individuals with comorbid psychiatric conditions. Administration in elderly individuals and acutely ill patients requires caution to prevent the accumulation of active metabolites. Extra precautions should be taken&#x000a0;in critically ill individuals as dose accumulation can occur.<xref ref-type="bibr" rid="article-25118.r12">[12]</xref><xref ref-type="bibr" rid="article-25118.r13">[13]</xref></p>
      </sec>
      <sec id="article-25118.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Frequent monitoring of blood levels of midazolam and its metabolites is a requirement during the treatment of midazolam overdose. Levels of midazolam and its metabolites can are measurable in blood, plasma, and serum. Monitoring is essential for elderly individuals and individuals with liver and kidney disease. The elimination of both the drug and its metabolite decreases with renal insufficiency. Monitoring is also necessary for drug interactions with erythromycin, clarithromycin, diltiazem, sertraline, protease inhibitors, rifampin, phenytoin, phenobarbital, carbamazepine, opioids, antipsychotics, and alcohol. Induction and inhibition of CYP450 3A4 play a role in decreased and increased drug levels in the circulation. Grapefruit juice reduces the activity of the CYP 450 enzyme and increases the level of the drug. St. John's wort&#x000a0;induces the enzyme and reduces the blood level of midazolam.<xref ref-type="bibr" rid="article-25118.r1">[1]</xref><xref ref-type="bibr" rid="article-25118.r14">[14]</xref><xref ref-type="bibr" rid="article-25118.r7">[7]</xref></p>
      </sec>
      <sec id="article-25118.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicity with midazolam is rare but can happen when combined with other CNS depressants like alcohol, opioids, and other tricyclic antidepressants. The risk increases with intravenous administration and in elderly individuals with COPD. Symptoms of overdose include ataxia, nystagmus, hypotension, slurred speech, slurred speech, impaired motor coordination, coma, and death. Impaired reflexes, impaired balance and dizziness, dysarthria, and vasomotor collapse can also occur. Flumazenil is the antidote for midazolam toxicity.<xref ref-type="bibr" rid="article-25118.r15">[15]</xref> Supportive treatment is the initial therapy course. Activated charcoal is an option&#x000a0;within 1 hour of intoxication. In many instances, flumazenil&#x000a0;is not prudent, as it can precipitate seizures when used in a mixed overdose of CNS depressants. Rapid intravenous infusion in elderly individuals having COPD can also result in&#x000a0;an overdose.<xref ref-type="bibr" rid="article-25118.r15">[15]</xref><xref ref-type="bibr" rid="article-25118.r6">[6]</xref></p>
      </sec>
      <sec id="article-25118.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All healthcare workers who use midazolam should know what to do in the event of an overdose. Resuscitative equipment and flumazenil must be available in the room when using this agent. The drug is relatively safe but is known to cause respiratory depression, especially when combined with fentanyl. Interprofessional teamwork that includes clinicians, mid-level practitioners, nurses, and pharmacists will yield better results and minimize adverse reactions with midazolam through coordinated monitoring and supportive patient counseling, leading to improved patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-25118.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25118&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25118">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25118/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25118">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25118.s11">
        <title>References</title>
        <ref id="article-25118.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reves</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Fragen</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Vinik</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Midazolam: pharmacology and uses.</article-title>
            <source>Anesthesiology</source>
            <year>1985</year>
            <month>Mar</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>310</fpage>
            <page-range>310-24</page-range>
            <pub-id pub-id-type="pmid">3156545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Appleton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Macleod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martland</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2008</year>
            <month>Jul</month>
            <day>16</day>
            <issue>3</issue>
            <fpage>CD001905</fpage>
            <pub-id pub-id-type="pmid">18646081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Status epilepticus: an evidence based guide.</article-title>
            <source>BMJ</source>
            <year>2005</year>
            <month>Sep</month>
            <day>24</day>
            <volume>331</volume>
            <issue>7518</issue>
            <fpage>673</fpage>
            <page-range>673-7</page-range>
            <pub-id pub-id-type="pmid">16179702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richter</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Current theories about the mechanisms of benzodiazepines and neuroleptic drugs.</article-title>
            <source>Anesthesiology</source>
            <year>1981</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-72</page-range>
            <pub-id pub-id-type="pmid">6109471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spina</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Ensom</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetic monitoring of midazolam in critically ill patients.</article-title>
            <source>Pharmacotherapy</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>389</fpage>
            <page-range>389-98</page-range>
            <pub-id pub-id-type="pmid">17316150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olkkola</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Ahonen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Midazolam and other benzodiazepines.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2008</year>
            <issue>182</issue>
            <fpage>335</fpage>
            <page-range>335-60</page-range>
            <pub-id pub-id-type="pmid">18175099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cloyd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gates</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>118</volume>
            <issue>2</issue>
            <fpage>69</fpage>
            <page-range>69-86</page-range>
            <pub-id pub-id-type="pmid">18384456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korttila</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aromaa</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Venous complications after intravenous injection of diazepam, flunitrazepam, thiopentone and etomidate.</article-title>
            <source>Acta Anaesthesiol Scand</source>
            <year>1980</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>227</fpage>
            <page-range>227-30</page-range>
            <pub-id pub-id-type="pmid">6108669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vermeeren</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Residual effects of hypnotics: epidemiology and clinical implications.</article-title>
            <source>CNS Drugs</source>
            <year>2004</year>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>297</fpage>
            <page-range>297-328</page-range>
            <pub-id pub-id-type="pmid">15089115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menc&#x000ed;a</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Herce</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Freddi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Analgesia and sedation in children: practical approach for the most frequent situations.</article-title>
            <source>J Pediatr (Rio J)</source>
            <year>2007</year>
            <month>May</month>
            <volume>83</volume>
            <issue>2 Suppl</issue>
            <fpage>S71</fpage>
            <page-range>S71-82</page-range>
            <pub-id pub-id-type="pmid">17530139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McElhatton</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>The effects of benzodiazepine use during pregnancy and lactation.</article-title>
            <source>Reprod Toxicol</source>
            <year>1994</year>
            <season>Nov-Dec</season>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>461</fpage>
            <page-range>461-75</page-range>
            <pub-id pub-id-type="pmid">7881198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suri</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>EVALUATION OF MIDAZOLAM AND DIAZEPAM FOR PRE-OPERATIVE SEDATION.</article-title>
            <source>Med J Armed Forces India</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>287</fpage>
            <page-range>287-292</page-range>
            <pub-id pub-id-type="pmid">28790742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verbeeck</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>12</issue>
            <fpage>1147</fpage>
            <page-range>1147-61</page-range>
            <pub-id pub-id-type="pmid">18762933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bushra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aslam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>AY</given-names>
              </name>
            </person-group>
            <article-title>Food-drug interactions.</article-title>
            <source>Oman Med J</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>77</fpage>
            <page-range>77-83</page-range>
            <pub-id pub-id-type="pmid">22043389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25118.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nordt</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Midazolam: a review of therapeutic uses and toxicity.</article-title>
            <source>J Emerg Med</source>
            <year>1997</year>
            <season>May-Jun</season>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>357</fpage>
            <page-range>357-65</page-range>
            <pub-id pub-id-type="pmid">9258787</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
